A New Highly Specific Buprenorphine Immunoassay for Monitoring Buprenorphine Compliance and Abuse
Open Access
- 14 March 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 36 (3), 201-206
- https://doi.org/10.1093/jat/bks003
Abstract
Urine buprenorphine screening is utilized to assess buprenorphine compliance and to detect illicit use. Robust screening assays should be specific for buprenorphine without cross-reactivity with other opioids, which are frequently present in patients treated for opioid addiction and chronic pain. We evaluated the new Lin-Zhi urine buprenorphine enzyme immunoassay (EIA) as a potentially more specific alternative to the Microgenics cloned enzyme donor immunoassay (CEDIA) by using 149 urines originating from patients treated for chronic pain and opioid addiction. The EIA methodology offered specific detection of buprenorphine use (100%) (106/106) and provided superior overall agreement with liquid chromatography–tandem mass spectrometry, 95% (142/149) and 91% (135/149) using 5 ng/mL (EIA[5]) and 10 ng/mL (EIA[10]) cutoffs, respectively, compared to CEDIA, 79% (117/149). CEDIA generated 27 false positives, most of which were observed in patients positive for other opioids, providing an overall specificity of 75% (79/106). CEDIA also demonstrated interference from structurally unrelated drugs, chloroquine and hydroxychloroquine. CEDIA and EIA[5] yielded similar sensitivities, both detecting 96% (22/23) of positive samples from patients prescribed buprenorphine, and 88% (38/43) and 81% (35/43), respectively, of all positive samples (illicit and prescribed users). The EIA methodology provides highly specific and sensitive detection of buprenorphine use, without the potential for opioid cross-reactivity.Keywords
This publication has 10 references indexed in Scilit:
- Analysis and interpretation of drug testing results from patients on chronic pain therapy: a clinical laboratory perspectivecclm, 2009
- Opioids and the treatment of chronic pain: Controversies, current status, and future directions.Experimental and Clinical Psychopharmacology, 2008
- Urinary Buprenorphine Concentrations in Patients Treated with Suboxone(R); as Determined by Liquid Chromatography-Mass Spectrometry and CEDIA ImmunoassayJournal of Analytical Toxicology, 2008
- Effect of Tramadol Use on Three Point-of-Care and One Instrument-Based Immunoassays for Urine BuprenorphineJournal of Analytical Toxicology, 2008
- Opioid Antagonists, Partial Agonists, and Agonists/Antagonists: The Role of OfficeBased DetoxificationPain Physician, 2008
- Comparison of three commercial tests for buprenorphine screening in urineAnnals of Clinical Biochemistry: International Journal of Laboratory Medicine, 2007
- The In Vivo Glucuronidation of Buprenorphine and Norbuprenorphine Determined by Liquid Chromatography-Electrospray Ionization-Tandem Mass SpectrometryTherapeutic Drug Monitoring, 2006
- Evaluation of Buprenorphine CEDIA Assay versus GC-MS and ELISA using Urine Samples from Patients in Substitution TreatmentJournal of Analytical Toxicology, 2005
- Cross-reactivity of the CEDIA buprenorphine assay with opiates: an Austrian phenomenon?International journal of legal medicine, 2005
- Urine drug testing in pain medicineJournal of Pain and Symptom Management, 2004